ABVX Latest Headlines

Palisade Bio jumps following Oppenheimer outperform initiation

at seekingalpha.com (Thu, 23-Jul 11:13 AM)

Abivax Secures $920 Million Through Full Exercise of Underwriters' Option: Funding Fuels Late-Stage IBD Drug Push

Market Chameleon (Thu, 2-Jul 11:44 AM)

Abivax’s $800M Upsized ADS Offering Priced at Premium: Extended Cash Runway Signals Ambitious US Plans

Market Chameleon (Wed, 1-Jul 8:58 AM)

Abivax Reports Meaningful Long-Term Efficacy and Safety Results for Obefazimod in Refractory Ulcerative Colitis

Market Chameleon (Tue, 30-Jun 10:29 AM)

ABVX Faces Shareholder Investigation as Rare Malignancy Cases Surface in Phase 3 Trial

Market Chameleon (Thu, 4-Jun 11:08 AM)

ABVX Phase 2 Data Draws Spotlight to Chronic Inflammatory Disease Innovation

Market Chameleon (Thu, 28-May 8:40 AM)

Abivax Shareholders Green-Light All Proposals at 2026 Annual General Meeting: Focus Sharpens on Phase 3 Developments

Market Chameleon (Tue, 12-May 9:13 AM)

Abivax Locks in $45M Offering and Retires Royalty Certificates, Extending Cash Runway Into Q4 2027

Market Chameleon (Tue, 5-May 7:08 AM)